Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CN National Reimbursement Drug List Raises Requirements on Innovative Drugs: Report
Recommend 7 Positive 12 Negative 2 |
||||
|
||||
|
China's National Reimbursement Drug List (NRDL) for 2024 is being adjusted, and the rate of drug varieties outside the List that pass the expert review is less than 50%, the Chinese media quoted multiple sources. The requirements for innovative drugs in the NRDL this year are higher than those in previous years, and the pass rate this year drops compared to last year's more than 60%, the report also indicated. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
